Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 5/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1019317 | 0.88 | ACKR3 (0.52) | ACKR3CHRM1LMNACNR2MAPT | |
| SCHEMBL12707429 | 0.87 | ACKR3 (0.48) | ACKR3CHRM1LMNACNR2MAPT | |
| SCHEMBL1019939 | 0.87 | ACKR3 (0.63) | ACKR3CHRM1LMNACNR2MAPT | |
| SCHEMBL13069582 | 0.82 | ACKR3 (0.57) | ACKR3LMNACNR2MAPTTP53 | |
| SCHEMBL12707327 | 0.82 | ACKR3 (0.52) | ACKR3CHRM1CNR2MAPTTP53 | |
| SCHEMBL14535528 | 0.78 | ACKR3 (0.52) | ACKR3LMNACNR2MAPTTP53 | |
| SCHEMBL12707401 | 0.77 | ACKR3 (0.48) | ACKR3CHRM1LMNACNR2MAPT | |
| SCHEMBL12707262 | 0.77 | ACKR3 (0.46) | ACKR3CHRM1LMNACNR2MAPT | |
| SCHEMBL1549337 | 0.76 | CHRM1 (0.74) | CHRM1LMNAMAPT | |
| SCHEMBL13069569 | 0.76 | ACKR3 (0.52) | ACKR3LMNACNR2MAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1954274-B1 | SUBSTITUTED QUINOLONES AND METHODS OF USE | CHEMOCENTRYX INC (US) | 2010-11-03 | — | — | EP | disclosed |
| WO-2007059108-A2 | SUBSTITUTED QUINOLONES AND METHODS OF USE | CHEMOCENTRYX, INC. (US) | 2007-05-24 | — | — | WO | disclosed |